Reactivation of chronic hepatitis B infection following intensive chemotherapy and successful treatment with lamivudine: A case report and review of the literature

Annals of Oncology

Volumn 12, Issue 1, 2001, Pages 123-129

  Wasif Saif, M ^a   Little, R F ^a   Hamilton, J M ^a   Allegra, C J ^a   Wilson, W H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

'Rebound effect'; Chemotherapy; Chronic hepatitis B. corticosteroids; Fulminant hepatitis; Immunosuppression; Interferon; Lamivudine (3TC); Plasma exchange

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GLUCOSE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN T CELL LEUKEMIA VIRUS ANTIBODY; IMMUNOSUPPRESSIVE AGENT; LACTATE DEHYDROGENASE; LAMIVUDINE; NUCLEOSIDE ANALOG; PREDNISONE; PROTEIN; PROTHROMBIN; THROMBOPLASTIN; UNINDEXED DRUG; VINCRISTINE; VIRUS ANTIBODY; VIRUS DNA;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHRONIC HEPATITIS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; EARLY DIAGNOSIS; HEPATITIS B; HISTOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FUNCTION TEST; LIVER INJURY; MALE; MEDICAL LITERATURE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; SERUM; TREATMENT OUTCOME; VIRUS CARRIER; VIRUS INHIBITION; VIRUS REACTIVATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HEPATITIS B, CHRONIC; HUMANS; IMMUNOCOMPROMISED HOST; LAMIVUDINE; LIVER; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECURRENCE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 0035135814     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008350507748     Document Type: Article

References (33)

1. Subacute and chronic active hepatitis after withdrawl of chemotherapy
2. Fulminant hepatic failure in leukemia and choriocarcinoma related to withdrawl of cytotoxic drug therapy
3. A case of fulminant hepatitis developing in a HBsAg carrier after chemotherapy of malignant lymphoma
4. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy
5. Fulminant hepatitis due to reactivation of chronic hepatitis B virus infection after allogenic bone marrow transplantation
6. Acute liver decompensation on withdrawl of cytotoxic chemotherapy and immunosuppressive therapy in hepatitis B carriers
7. Acute hepatic injury after withdrawl of immunosuppressive chemotherapy in patients with hepatitis B
8. Hepatitis B infection in patients with lymphoma
9. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study
10. Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematologic malignancies
11. Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment
12. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies
13. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B
14. Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis
15. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis
16. Mutations in core nucleotide sequence of hepatitis B virus correlate with fulminant and severe hepatitis
17. Hepatitis B virus precore mutation and fulminant hepatitis in the US
18. The development of a mutation in the precore region of the hepatitis B virus in a chronically infected individual
19. Hepatitis B virus strains with mutations in the core promotor in patients with fulminant hepatitis
20. Hepatitis B virus and hepatitis D virus
21. Withdrawal of immunosuppressive therapy in allogenic bone marrow transplantation reactivates chronic viral hepatitis C
22. Fulminant hepatitis on withdrawl of chemotherapy in carriers of hepatitis C virus
23. Randomised trial of steroid therapy in acute liver failure
24. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients
25. Successful treatment with lamuvidine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-hodgkin's lymphoma
26. Recovery from life-threatening,corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis of hepatitis B associated with lamuvidine therapy
27. Lamuvidine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation
28. Lamuvidine therapy for chemotherapy-induced reactivation of hepatitis B virus infection
29. Lamuvidine in the treatment of hepatitis B virusreactivation during cytotoxic chemotherapy
30. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group
31. Combination therapy with alpha-interferon and lamuvidine in patients with chronic hepatitis B and HIV infection